GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Cyclically Adjusted PB Ratio

Imunon (FRA:CBO) Cyclically Adjusted PB Ratio : 0.06 (As of Jun. 02, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Imunon Cyclically Adjusted PB Ratio?

As of today (2025-06-02), Imunon's current share price is €2.46. Imunon's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €42.74. Imunon's Cyclically Adjusted PB Ratio for today is 0.06.

The historical rank and industry rank for Imunon's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:CBO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.67
Current: 0.05

During the past years, Imunon's highest Cyclically Adjusted PB Ratio was 0.67. The lowest was 0.01. And the median was 0.06.

FRA:CBO's Cyclically Adjusted PB Ratio is ranked better than
92.86% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs FRA:CBO: 0.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Imunon's adjusted book value per share data for the three months ended in Mar. 2025 was €0.029. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €42.74 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Imunon's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted PB Ratio Chart

Imunon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.04 0.01 0.01 0.02

Imunon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.02 0.02 0.02

Competitive Comparison of Imunon's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Imunon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted PB Ratio falls into.


;
;

Imunon Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Imunon's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.46/42.74
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imunon's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Imunon's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.029/134.9266*134.9266
=0.029

Current CPI (Mar. 2025) = 134.9266.

Imunon Quarterly Data

Book Value per Share CPI Adj_Book
201506 235.755 100.684 315.936
201509 203.173 100.392 273.065
201512 168.595 99.792 227.953
201603 122.741 100.470 164.835
201606 119.480 101.688 158.534
201609 75.968 101.861 100.628
201612 42.792 101.863 56.682
201703 21.625 102.862 28.366
201706 15.020 103.349 19.609
201709 7.964 104.136 10.319
201712 19.589 104.011 25.411
201803 16.186 105.290 20.742
201806 13.855 106.317 17.583
201809 10.860 106.507 13.758
201812 14.611 105.998 18.599
201903 14.444 107.251 18.171
201906 11.904 108.070 14.862
201909 9.569 108.329 11.918
201912 8.454 108.420 10.521
202003 7.523 108.902 9.321
202006 9.705 108.767 12.039
202009 6.570 109.815 8.072
202012 5.639 109.897 6.923
202103 9.231 111.754 11.145
202106 9.212 114.631 10.843
202109 8.740 115.734 10.189
202112 8.556 117.630 9.814
202203 7.281 121.301 8.099
202206 6.269 125.017 6.766
202209 5.883 125.227 6.339
202212 3.723 125.222 4.012
202303 2.736 127.348 2.899
202306 2.146 128.729 2.249
202309 1.808 129.860 1.879
202312 1.306 129.419 1.362
202403 0.832 131.776 0.852
202406 0.370 132.554 0.377
202409 0.509 133.029 0.516
202412 0.279 133.157 0.283
202503 0.029 134.927 0.029

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon  (FRA:CBO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Imunon Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Industry
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines